CMA reimposes excessive pricing fines on Pfizer and Flynn
Shutterstock/Mdisk
The UK’s Competition and Markets Authority has collectively fined drugmakers Pfizer and Flynn Pharma nearly £70 million after an appellate court ordered it to reassess its original decision to punish the companies for excessively pricing a lifesaving anti-epilepsy drug.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now